Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 4/20 | 0.49 |
| ▸ | CTSS | P25774 | 4/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23455707 | 1.00 | ATM (0.53) | ATMCTSLCTSSCTSBCTSK | |
| SCHEMBL17352430 | 1.00 | ATM (0.53) | ATMCTSLCTSSCTSBCTSK | |
| SCHEMBL23455705 | 1.00 | ATM (0.53) | ATMCTSLCTSSCTSBCTSK | |
| SCHEMBL15936982 | 0.92 | ATM (0.52) | ATMCTSLCTSSCTSBCTSK | |
| SCHEMBL23392518 | 0.92 | ATM (0.52) | ATMCTSLCTSSCTSBCTSK | |
| SCHEMBL17351827 | 0.92 | ATM (0.52) | ATMCTSLCTSSCTSBCTSK | |
| SCHEMBL25693847 | 0.91 | ATM (0.51) | ATMCTSLCTSSCTSBCTSK | |
| SCHEMBL15936991 | 0.89 | ATM (0.49) | ATMCTSLCTSSCTSBCTSK | |
| SCHEMBL6475821 | 0.86 | CTSL (0.48) | ATMCTSLCTSSCTSBCTSK | |
| SCHEMBL14070425 | 0.85 | ATM (0.47) | ATMCTSLCTSSCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112239-A1 | PROCESS AND INTERMEDIATES FOR SYNTHESIS OF PEPTIDE COMPOUNDS | INNOVIVA TRC HOLDINGS LLC | 2022-04-14 | — | — | US | disclosed |
| EP-3916003-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | Naurex, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3171941-B1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200199173-A1 | PROCESS AND INTERMEDIATES FOR SYNTHESIS OF PEPTIDE COMPOUNDS | INNOVIVA TRC HOLDINGS LLC | 2020-06-25 | — | — | US | disclosed |
| US-10273239-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190031715-A1 | PROCESS AND INTERMEDIATES FOR SYNTHESIS OF PEPTIDE COMPOUNDS | NAUREX INC (US) | 2019-01-31 | — | — | US | disclosed |
| US-20180258139-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX INC (US) | 2018-09-13 | — | — | US | disclosed |
| US-20180179217-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-06-28 | — | — | US | disclosed |
| US-20180179217-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-06-28 | — | — | US | disclosed |
| US-9994614-B2 | N-methyl-D-aspartate receptor modulators and methods of making and using same | NAUREX, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170210779-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX INC (US) | 2017-07-27 | — | — | US | disclosed |
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | disclosed |
| EP-1413580-A1 | Furanone derivatives as inhibitors of Cathepsin S | Medivir UK Ltd (GB) | 2004-04-28 | — | — | EP | disclosed |
| EP-1178986-B1 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | MEDIVIR UK LTD (GB) | 2004-02-25 | — | — | EP | disclosed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | disclosed |
| EP-1178986-A2 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | Medivir UK Ltd (GB) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000069855-A2 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | MEDIVIR UK LIMITED (GB) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112239-A1 | PROCESS AND INTERMEDIATES FOR SYNTHESIS OF PEPTIDE COMPOUNDS | PEPD, VIP, IAPP | ATM 2989/4885CTSL 46/4885CTSS 1177/4885 |
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | ATM 2196/4885CTSL 3751/4885CTSS 4304/4885 |
| US-20180258139-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | GRIN1, GRIN2A, GRIN3A | ATM 3114/4885CTSL 3260/4885CTSS 3757/4885 |
| US-20190031715-A1 | PROCESS AND INTERMEDIATES FOR SYNTHESIS OF PEPTIDE COMPOUNDS | PEPD, VIP, IAPP | ATM 2989/4885CTSL 46/4885CTSS 1177/4885 |
| US-20050020588-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | ATM 2255/4885CTSL 11/4885CTSS 1/4885 |
| US-10273239-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | ATM 2196/4885CTSL 3751/4885CTSS 4304/4885 |
| US-20170210779-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | GRIN1, GRIN2A, GRIN3A | ATM 3114/4885CTSL 3260/4885CTSS 3757/4885 |
| US-20180179217-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | ATM 2196/4885CTSL 3751/4885CTSS 4304/4885 |
| US-20200199173-A1 | PROCESS AND INTERMEDIATES FOR SYNTHESIS OF PEPTIDE COMPOUNDS | PEPD, VIP, IAPP | ATM 2989/4885CTSL 46/4885CTSS 1177/4885 |
| US-20030203900-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | ATM 2255/4885CTSL 11/4885CTSS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.